TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05021978
Drug: Part B: 120 mg PRAX-944
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment with titration
Study: NCT05021978
Drug: Part B: 120 mg PRAX-944 and Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment with titration followed by placebo
Study: NCT01048619
Drug: ON 01910.Na
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
Study: NCT03201601
Drug: Myoinositol
Normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Study: NCT04056325
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy, oral administration, single dose, matching number of tablets
Study: NCT04444726
Drug: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: thin film of the cream is being applied to the affected areas for 2 times per day.
Study: NCT01128634
Drug: GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Study: NCT01128634
Drug: GW573719/GW573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Study: NCT02387853
Drug: LEO 90100
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02686749
Drug: FDA approved anti arrhythmic drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
Study: NCT01408173
Drug: NPC-11 for intravenous or oral administration.
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
Study: NCT01394796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment is given.
Study: NCT03279744
Drug: Radion™-pdt
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
Study: NCT01577992
Drug: Levodopa test
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
Study: NCT04291885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV infusion
Study: NCT03516188
Drug: Alginate-antacid group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
Study: NCT03516188
Drug: Non antacid alginate group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
Study: NCT03873116
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered orally once daily
Study: NCT00240513
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsules OD for 3 months
Study: NCT00240513
Drug: Minocycline plus tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
Study: NCT00003475
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00597220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00577304
Drug: Topical AmphiMatrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
Study: NCT00658359
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 tablets dosed BID Months 12-72
Study: NCT02249546
Drug: PPI-amoxicillin-clarithromycin
Normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple therapy
Study: NCT01085331
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Study: NCT01197846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00132665
Drug: B: CBDCA and Radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: B: CBDCA and Radiotherapy
Study: NCT02910531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Already mentioned in arm/group descriptions.
Study: NCT03636152
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo for the control group.
Study: NCT00281931
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00472576
Drug: MK-0657
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
Study: NCT00472576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily double-blind administration of placebo
Study: NCT02276443
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard chemotherapy
Study: NCT01046487
Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os
Study: NCT01046487
Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os
Study: NCT04502862
Drug: SAR231893
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study: NCT04502862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study: NCT01046487
Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os
Study: NCT01716221
Drug: Placebo & Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01670552
Drug: Naproxen + Esomeprazole
Normalized name: esomeprazole / naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
Study: NCT01336647
Drug: Group A - Low-Dose Ha44 0.37% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
Study: NCT01336647
Drug: Group B - High Dose Ha44 Gel 0.74% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose Ha44 Gel applied to scalp and hair for 10 minutes
Study: NCT01336647
Drug: Group C - Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
Study: NCT02288741
Drug: Tumor-reduction chemotherapy and stem cell mobilization
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
Study: NCT02288741
Drug: Tandem high-dose chemotherapy (melphalan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
Study: NCT01328132
Drug: 25% albumin
Normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
Study: NCT02132026
Drug: Alendronic Acid
Normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02132026
Drug: Alendronic Acid Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
Study: NCT01497496
Drug: High Dose Methylprednisolone (HDMP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
Study: NCT02792686
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Administration
Study: NCT01217229
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
Study: NCT00953849
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (400 mg twice daily)
Study: NCT03146416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02952820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00335595
Drug: XELOXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
Study: NCT00335595
Drug: XELOXA-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks
Study: NCT02319018
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02319018
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01297829
Drug: Intravenous Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg IV ibuprofen 30 minutes preoperatively
Study: NCT01599637
Drug: IGE025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Study: NCT01599637
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Study: NCT04139018
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel is prepared with poloxamers and no active ingredients.
Study: NCT00411684
Drug: CDB-2914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02873416
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study: NCT03192735
Drug: ApatinibMesylateTablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
Study: NCT01040910
Drug: smoking cigarettes with placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
Study: NCT00036985
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00036985
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04171843
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT02010359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT04731740
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators' choice
Study: NCT03123627
Drug: New profilaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
Study: NCT02226380
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
Study: NCT02157883
Drug: AZD9291
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Study: NCT01767090
Drug: ASP1707
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01767090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01789476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered using same dosing algorithm as the active arm
Study: NCT00967070
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
Study: NCT04123743
Drug: Trigonella foenum-graceum extract topical cream
Normalized name: Trigonella foenum-graecum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream containing Trigonella foenum-graceum extract
Study: NCT01016249
Drug: Treatment 1. (5% Hypertonic saline + Epinephrine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Study: NCT01016249
Drug: Treatment 3. (3% Hypertonic saline + Epinephrine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Study: NCT01016249
Drug: Treatment 2. (Normal saline + Epinephrine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Study: NCT02713893
Drug: Placebo intravaginal cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01741558
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
Study: NCT02434666
Drug: CPC-201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01395420
Drug: CAZ104
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT03339999
Drug: AGN-242428
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-242428 administered as an oral capsule(s) once daily.
Study: NCT03339999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as an oral capsule(s) once daily.
Study: NCT01396811
Drug: 33525
Normalized name: POUCH,CLOSED,KARAYA SEAL H#3325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 14 days
Study: NCT01396811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 14 days
Study: NCT04262843
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02218034
Drug: AGN-190168 Formulation 1
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study: NCT02218034
Drug: AGN-190168 Formulation 2
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Study: NCT01582269
Drug: LY2157299 monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered as tablets
Study: NCT01582269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered as tablets
Study: NCT00131027
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00131027
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00131027
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 g/sqm (high dose)
Study: NCT00131027
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00131027
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00131027
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 g/sqm (intermediate dose)
Study: NCT03287089
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03173248
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT03173248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT02140996
Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01388946
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03504501
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral application prior to transcranial magnetic stimulation intervention
Study: NCT02675660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules once daily
Study: NCT00509275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01935778
Drug: Docetaxel and capecitabine and oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
Study: NCT01935778
Drug: capecitabine and oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
Study: NCT02648919
Drug: Noni extract
Normalized name: noni fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.